- Home
- STTK
STTK
Shattuck Labs Inc.
as 12-18-2024 12:43pm EST
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 54.4M | IPO Year: | 2020 |
| Target Price: | $2.00 | AVG Volume (30 days): | 332.9K |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.94 - $11.76 | Next Earning Date: | 11-14-2024 |
| Revenue: | $6,435,000 | Revenue Growth: | 382.75% |
| Revenue Growth (this year): | 313.04% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Shattuck Labs Inc. (STTK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | STTK | Director10% Owner | Dec 4 '24 | Buy | $1.25 | 133,371 | $166,713.75 | 5,539,724 | |
| Redmile Group, LLC | STTK | Director10% Owner | Dec 4 '24 | Sell | $1.25 | 133,371 | $166,713.75 | 5,406,353 | |
| Schreiber Taylor | STTK | Chief Executive Officer | Oct 7 '24 | Buy | $1.21 | 36,500 | $44,219.75 | 71,002 |
Latest Shattuck Labs Inc. News
STTK Breaking Stock News: Dive into STTK Ticker-Specific Updates for Smart Investing
GlobeNewswire
23 days ago
Shattuck Labs Announces Participation in Upcoming December Conferences
Simply Wall St.
a month ago
Shattuck Labs Third Quarter 2024 Earnings: Beats Expectations
TipRanks
a month ago
Shattuck Labs sees cash runway into 2027
GlobeNewswire
a month ago
Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Zacks
2 months ago
Down -64.19% in 4 Weeks, Here's Why Shattuck Labs (STTK) Looks Ripe for a Turnaround
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 10/09/2024
Zacks
2 months ago
After Plunging -68.96% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK)
MT Newswires
3 months ago
Top Midday Decliners
Compare STTK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STTK Shattuck Labs Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.